WNT5A and central nervous system cancer: Targeting low taurine synthesis or modulating Wnt5a promoter methylation may be a novel therapeutic strategy for the treatment of gliomas, and inhibitors of low taurine synthesis have the potential to reduce glioma cell invasion by altering the epigenetic regulation of Wnt5a.